Galectin Therapeutics Inc. 2012 Form 10-K Summary
Business Context and Reporting Period
Galectin Therapeutics Inc. is a development-stage biotechnology company focused on carbohydrate-based inhibitors of galectin proteins for fibrotic disease and cancer. The filing covers the fiscal year ended December 31, 2012; it was signed March 29, 2013. The company had no products approved for sale and had generated no significant revenue since inception.
- GR-MD-02: Lead candidate for NASH with advanced liver fibrosis; an FDA IND was submitted in January 2013, and the FDA allowed a Phase 1 U.S. trial to proceed on March 1, 2013.
- GM-CT-01: In a Phase 1/2 European trial with a tumor vaccine for advanced melanoma. The company did not control the trial, and no U.S. trial was underway.
- The company had five full-time employees and relied substantially on contract research, clinical, manufacturing, and financial service providers.
Financial Results and Key Metrics
| Metric | 2012 | 2011 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No revenue generated |
| Research and development expense | $4.527 million | $3.552 million | Up 27% |
| General and administrative expense | $5.372 million | $6.857 million | Down 22% |
| Total operating expenses | $9.899 million | $10.409 million | Down $0.510 million |
| Operating loss | $9.899 million | $10.409 million | Improved $0.510 million |
| Net loss | $9.675 million | $10.915 million | Improved $1.240 million |
| Net loss applicable to common stockholders | $10.881 million | $12.713 million | Improved $1.832 million |
| Basic and diluted loss per share | $0.72 loss | $1.06 loss | Improved |
| Net cash used in operations | $7.500 million | $5.676 million | Use increased $1.824 million |
| Cash and cash equivalents at year-end | $9.364 million | $6.397 million | Up $2.967 million |
Gross profit and operating margins were not meaningful because the company had no revenue. Stock-based compensation was $2.792 million in 2012, compared with $3.245 million in 2011. Cumulative net losses applicable to common stockholders reached $80.272 million through December 31, 2012.
The company reported no warrant liabilities at December 31, 2012 and no interest expense for the year. Balance-sheet liabilities totaled $1.644 million, while redeemable convertible preferred stock totaled approximately $6.752 million. The company also carried a $1.0 million accrued separation obligation relating to its former chief executive officer, payable if specified milestones occur.
Material Changes Versus the Prior Comparable Period
- Research and development spending increased by $975,000, primarily because of expanded preclinical fibrosis work and preparation for the GR-MD-02 IND and Phase 1 program.
- General and administrative expense declined by $1.485 million, largely because of lower legal, investor-relations, business-development, and stock-compensation costs. The 2011 period included recognition of a $1.0 million separation obligation and $162,000 of litigation-related expense.
- Operating cash use increased 32% to $7.500 million despite the lower operating loss, reflecting increased development activity and working-capital changes.
- On March 28, 2012, the company raised $12.0 million gross, or $10.403 million net, through an offering of 2,666,722 common shares and warrants to purchase 1,333,361 shares. The company also completed a one-for-six reverse stock split and began trading on the NASDAQ Capital Market.
- Common shares outstanding increased from 12.920 million at year-end 2011 to 16.061 million at year-end 2012. Outstanding warrants increased to 7.424 million from 6.673 million, creating substantial potential dilution.
- The company terminated its PROCAPS agreement effective September 29, 2012, after PROCAPS failed to obtain Colombian regulatory approval. The previously deferred $200,000 payment was recognized as other income in 2012.
Guidance, Outlook, Risks, Contingencies, and Unusual Items
- Management expected substantial research and development spending and operating losses to continue for the foreseeable future.
- Management believed year-end unrestricted cash was sufficient to fund planned operations through the first quarter of 2014, but stated that additional capital would be required. Failure to raise capital by the end of the first quarter of 2014 could require significant curtailment, cessation of operations, or bankruptcy protection.
- The company expected to begin enrolling patients in the GR-MD-02 Phase 1 trial in the second quarter of 2013, with top-line results expected by late 2013 or early 2014. Subject to results and funding, a Phase 2 program could begin in mid-2014.
- The first stage of the GM-CT-01 melanoma study was expected to be completed in the second or third quarter of 2013. Further enrollment could depend on at least one response among the first six evaluable patients and on additional funding.
- In February 2013, the company entered into a CTI clinical services work order with an estimated budget of $2.155 million for the GR-MD-02 Phase 1 trial. It also committed $154,000 through December 2013 for a University of Georgia drug-discovery collaboration.
- Key risks include the need for recurring financing, clinical and regulatory failure, dependence on third parties, manufacturing and supply risks, competition, intellectual-property challenges, limited operating history, and potential stockholder dilution.
- The company accrued $1.0 million under the former CEO’s separation agreement. An arbitration demand filed by the company in March 2013 seeks to rescind or reform that agreement and potentially reverse the accrual; the outcome is uncertain. A related Massachusetts Wage Act lawsuit against current executives remained outstanding, with the company planning to indemnify them.
- The company’s Series B preferred stock carries cumulative dividends, redemption rights, security interests in certain circumstances, and significant consent and governance rights. The company also had approximately $5.204 million of Series C redemption value at year-end.
Most Important Facts for Investors to Verify
- Actual cash burn and remaining liquidity following commencement of the GR-MD-02 clinical program.
- Timing, enrollment, safety results, and efficacy signals from the GR-MD-02 and GM-CT-01 trials.
- Availability and terms of additional financing, including dilution from equity, warrants, preferred stock, or convertible securities.
- Conversion, redemption, dividend, voting, and consent rights attached to the preferred stock and their effect on common stockholders.
- Resolution and potential financial impact of the $1.0 million separation-payment dispute and related litigation.
- Regulatory status of each product candidate and whether any candidate can ultimately obtain FDA or foreign marketing approval.
- Patent ownership, pending applications, expiration dates, and potential infringement or validity challenges.